1. Genetic and environmental epidemiology of Alzheimer’s disease in arabs residing in Israel

   • Lindsay A. Farrer
   • Robert P. Friedland
   • Clinton T. Baldwin

   Genetics And Prevention Pages: 207 - 212

2. Enhancing brain and cognitive function of older adults through fitness training

   • Arthur F. Kramer
   • Stanley J. Colcombe
   • Andrew G. Webb

   Genetics And Prevention Pages: 213 - 221

3. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites

   • Shyamala Mruthinti
   • William D. Hill
   • Jerry J. Buccafusco

   Target Identification And Validation Pages: 223 - 232

4. β-secretase processing of the Alzheimer’s amyloid protein precursor (APP)

   • Laura Marlow
   • Melissa Cain
   • Kumar Sambamurti

   Target Identification And Validation Pages: 233 - 239

5. Hippocampal volume is associated with memory but not nonmemory cognitive performance in patients with mild cognitive impairment

   • Michael Grundman
   • Clifford R. Jack
   • the Alzheimer’s Disease Cooperative Study

   Early Detection Pages: 241 - 248

6. Characterization of radioiodinated ligand binding to amyloid β plaques

   • Mei-Ping Kung
   • Zhi-Ping Zhuang
   • Hank F. Kung

   Early Detection Pages: 249 - 253

7. Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives

   • Yanming Wang
   • Chester A. Mathis
   • William E. Klunk

   Early Detection Pages: 255 - 260

8. Peptide nucleic acids targeted to the amyloid precursor protein

   • Beth M. McMahon
   • Jennifer Stewart
   • Elliott Richelson

   Alzheimer’s Therapeutics: Anti-Amyloid Pages: 261 - 265

9. Drug discovery targeted to the Alzheimer’s APP mRNA 5′-untranslated region

   • Sandra Payton
   • Catherine M. Cahill
   • Jack T. Rogers

   Alzheimer’s Therapeutics: Anti-Amyloid Pages: 267 - 275

10. Potential use of estrogen-like drugs for the prevention of Alzheimer’s disease

    • Jonathan D. Smith
    • Justine A. Levin-Allerhand

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 277 - 281

11. Immunological approach for the treatment of Alzheimer’s disease

    • Beka Solomon

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 283 - 286

12. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer’s disease

    • Jerry P. Melchor
    • Robert Pawlak
    • Sidney Strickland

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 287 - 289

13. Novel glycosaminoglycan precursors as anti-amyloid agents, Part III

    • Robert Kisilevsky
    • Walter A. Szarek
    • Sandra Marone

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 291 - 297

14. Study of memapsin 2 (β-secretase) and strategy of inhibitor design

    • Jordan Tang
    • Arun K. Ghosh
    • Wanpin Chang

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 299 - 304

15. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening

    • Lei Chang
    • Lara Bakhos
    • William L. Klein

    Alzheimer’s Therapeutics: Anti-Amyloid Pages: 305 - 313

16. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP

    • Illana Gozes
    • Inna Divinsky
    • Avron D. Spier

    Alzheimer’s Therapeutics: Neuroprotection Pages: 315 - 322

17. Alzheimer’s therapeutics

    • Stephen M. Massa
    • Youmei Xie
    • Frank M. Longo

    Alzheimer’s Therapeutics: Neuroprotection Pages: 323 - 326

18. Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease

    • Marcos A. Marques
    • Keith A. Crutcher

    Alzheimer’s Therapeutics: Neuroprotection Pages: 327 - 337

19. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors

    • Antonie Rice
    • Mary L. Michaelis
    • Kenneth L. Audus

    Alzheimer’s Therapeutics: Neuroprotection Pages: 339 - 343

20. Structure-based rational design of chemical ligands for AMPA-subtype glutamate receptors

    • Lei Zeng
    • Can Hao Chen
    • Ming-Ming Zhou

    Alzheimer’s Therapeutics: Neuroprotection Pages: 345 - 348

21. M₁ muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease

    • Abraham Fisher
    • Zipora Pittel
    • Rachel Brandeis

    Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 349 - 356

22. Calpain inhibitors, a treatment for alzheimer’s disease

    • Fortunato Battaglia
    • Fabrizio Trinchese
    • Ottavio Arancio

    Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 357 - 362

23. Progress toward a high-affinity allosteric enhancer at muscarinic M₁ receptors

    • Sebastian Lazareno
    • Angela Popham
    • Nigel J. M. Birdsall

    Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 363 - 367

24. Acetylcholinesterase

    • Harry M. Greenblatt
    • Hay Dvir
    • Joel L. Sussman

    Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 369 - 383

25. Steroid hormones and cognitive functioning in aging men

    • Barbara B. Sherwin

    Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 385 - 393

26. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol

    • Suzana S. Petanceska
    • Steven DeRosa
    • Miguel Pappolla

    Alzheimer’s Therapeutics: Lipid Lowering Pages: 395 - 406

27. A position paper

    • D. Larry Sparks
    • Jean Lopez
    • the ADCLT Team

    Alzheimer’s Therapeutics: Lipid Lowering Pages: 407 - 410

28. Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against β-amyloid induced injury

    • D. Martin Watterson
    • Anastasia V. Velentza
    • Linda J. Van Eldik

    Alzheimer’s Therapeutics: Anti-Inflammation Pages: 411 - 423

29. Alzheimer neurofibrillary degeneration

    • Khalid Iqbal
    • Alejandra del C. Alonso
    • Inge Grundke-Iqbal

    Alzheimer’s Therapeutics: Anti-Tangle Pages: 425 - 429